Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT

Abstract

The risk of invasive aspergillosis (IA) is considered to be low among autologous HSCT recipients, but an increase in the incidence has been observed recently in this setting. The aim of the study was to assess the influence of immunosuppressive drugs (steroids, rituximab, fludarabine, thalidomide), used in treatment of lymphoid malignancies during 6 months of pretransplant period, on IA incidence after autologous HSCT. A total of 109 patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD) and multiple myeloma (MM), conditioned with carmustine, etoposide, cytarabine, melphalan or melphalan and transplanted with PBSC, were analyzed prospectively. Patients were monitored with twice-weekly galactomannan test. High-resolution computed tomograhy of the chest and bronchoscopy were performed in case of positive galactomanan test, persistent fever or pulmonary infiltrates. Documented IA was diagnosed in nine (8%) patients (three proven, six probable). The incidence of IA was comparable in NHL, HD and MM patients and not influenced by age, advanced disease or conditioning regimen. Factors significant for development of documented IA by univariate analysis were treatment with fludarabine (P=0.008) or rituximab (P=0.039). The only factor predicting documented IA by multivariate analysis was treatment with fludarabine (P=0.008). Patients treated with fludarabine or rituximab in pretransplant period are at risk of IA and require close monitoring and/or anti-mould prophylaxis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Marr KA, Carter RA, Crippa F, Wald A, Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.

    Article  PubMed  Google Scholar 

  2. Lin SJ, Schranz J, Teutsch SM . Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366.

    Article  CAS  PubMed  Google Scholar 

  3. Marr KA, Carter RA, Boeckh M, Martin P, Corey L . Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.

    Article  CAS  PubMed  Google Scholar 

  4. Gil L, Styczynski J, Komarnicki M . Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 2007; 35: 421–427.

    Article  CAS  PubMed  Google Scholar 

  5. Mennink-Kersten MA, Donnelly JP, Verweij PE . Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349–357.

    Article  CAS  PubMed  Google Scholar 

  6. Kedzierska A, Kochan P, Pietrzyk A, Kedzierska J . Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1 → 3)-beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis 2007; 26: 755–766.

    Article  CAS  PubMed  Google Scholar 

  7. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.

    Article  CAS  PubMed  Google Scholar 

  8. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751.

    Article  PubMed  Google Scholar 

  9. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250.

    Article  CAS  PubMed  Google Scholar 

  10. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006; 91: 986–989.

    PubMed  Google Scholar 

  11. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577–584.

    Article  CAS  PubMed  Google Scholar 

  12. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913–916.

    Article  PubMed  Google Scholar 

  13. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G . Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51: 288–296.

    Article  CAS  PubMed  Google Scholar 

  14. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147.

    Article  CAS  PubMed  Google Scholar 

  15. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M . Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610.

    Article  CAS  PubMed  Google Scholar 

  16. Muhlemann K, Wenger C, Zenhausern R, Tauber MG . Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19: 545–550.

    Article  CAS  PubMed  Google Scholar 

  17. Lionakis MS, Kontoyiannis DP . Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828–1838.

    Article  CAS  PubMed  Google Scholar 

  18. Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000; 30: 41–46.

    Article  CAS  PubMed  Google Scholar 

  19. Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999; 106: 191–197.

    Article  CAS  PubMed  Google Scholar 

  20. Jantunen E, Itala M, Lehtinen T, Kuittinen O, Koivunen E, Leppa S et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 2006; 76: 245–250.

    Article  CAS  PubMed  Google Scholar 

  21. Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A . Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42: 1015–1022.

    Article  CAS  PubMed  Google Scholar 

  22. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–984.

    Article  CAS  PubMed  Google Scholar 

  23. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262–1268.

    Article  CAS  PubMed  Google Scholar 

  24. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414–1420.

    Article  CAS  PubMed  Google Scholar 

  25. Frank DA, Mahajan S, Ritz J . Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999; 5: 444–447.

    Article  CAS  PubMed  Google Scholar 

  26. Cabanillas F, Liboy I, Pavia O, Rivera E . High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17: 1424–1427.

    Article  CAS  PubMed  Google Scholar 

  27. Tam CS, Wolf MM, Januszewicz EH, Grigg AP, Prince HM, Westerman D et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer 2004; 101: 2042–2049.

    Article  CAS  PubMed  Google Scholar 

  28. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

    Article  CAS  PubMed  Google Scholar 

  29. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106: 1538–1543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Shlomchik MJ, Craft JE, Mamula MJ . From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147–153.

    Article  CAS  PubMed  Google Scholar 

  31. Imashuku S, Teramura T, Morimoto A, Naya M, Kuroda H . Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant 2004; 33: 129–130.

    Article  CAS  PubMed  Google Scholar 

  32. Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47: 1570–1582.

    Article  PubMed  Google Scholar 

  33. Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R . Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374–377.

    Article  CAS  PubMed  Google Scholar 

  34. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G . Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–529.

    Article  CAS  PubMed  Google Scholar 

  35. Salazar R, Sola C, Maroto P, Tabernero JM, Brunet J, Verger G et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 27–33.

    Article  CAS  PubMed  Google Scholar 

  36. Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 2004; 73: 174–178.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L Gil.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gil, L., Kozlowska-Skrzypczak, M., Mol, A. et al. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 43, 121–126 (2009). https://doi.org/10.1038/bmt.2008.303

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.303

Keywords

This article is cited by

Search

Quick links